Prothena Corp. Plc (PRTA)
9.69
+0.08
(+0.83%)
USD |
NASDAQ |
Sep 02, 16:00
9.69
0.00 (0.00%)
After-Hours: 16:51
Prothena Research and Development Expense (TTM) : 64.95M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 64.95M |
| March 31, 2026 | 96.67M |
| December 31, 2025 | 134.85M |
| September 30, 2025 | 170.44M |
| June 30, 2025 | 192.22M |
| March 31, 2025 | 209.22M |
| December 31, 2024 | 222.52M |
| September 30, 2024 | 234.24M |
| June 30, 2024 | 241.43M |
| March 31, 2024 | 239.93M |
| December 31, 2023 | 220.57M |
| September 30, 2023 | 195.55M |
| June 30, 2023 | 177.50M |
| March 31, 2023 | 153.06M |
| December 31, 2022 | 135.56M |
| September 30, 2022 | 120.75M |
| June 30, 2022 | 98.88M |
| March 31, 2022 | 88.40M |
| December 31, 2021 | 82.28M |
| September 30, 2021 | 80.99M |
| June 30, 2021 | 84.60M |
| March 31, 2021 | 80.78M |
| December 31, 2020 | 74.88M |
| September 30, 2020 | 69.60M |
| June 30, 2020 | 60.48M |
| Date | Value |
|---|---|
| March 31, 2020 | 52.79M |
| December 31, 2019 | 50.84M |
| September 30, 2019 | 51.88M |
| June 30, 2019 | 57.90M |
| March 31, 2019 | 79.77M |
| December 31, 2018 | 101.18M |
| September 30, 2018 | 118.18M |
| June 30, 2018 | 140.98M |
| March 31, 2018 | 143.56M |
| December 31, 2017 | 134.55M |
| September 30, 2017 | 140.89M |
| June 30, 2017 | 126.41M |
| March 31, 2017 | 124.74M |
| December 31, 2016 | 119.53M |
| September 30, 2016 | 97.58M |
| June 30, 2016 | 87.93M |
| March 31, 2016 | 68.36M |
| December 31, 2015 | 58.44M |
| September 30, 2015 | 50.66M |
| June 30, 2015 | 43.86M |
| March 31, 2015 | 39.68M |
| December 31, 2014 | 38.45M |
| September 30, 2014 | 33.94M |
| June 30, 2014 | 29.90M |
| March 31, 2014 | 29.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alkermes Plc | 384.84M |
| Amarin Corp. Plc | 16.15M |
| Agenus, Inc. | 57.69M |
| Amgen, Inc. | 7.638B |
| Anika Therapeutics, Inc. | 27.45M |